Alex’s Lemonade Stand: RUNX1 Early Career Investigator Grant Program
Deadline: December 19, 2024
8 pm
Amount: $180,000 over 3 years (maximum $60,000 per year may be requested)
Purpose
About RRP
A research and advocacy venture committed to funding world-class, innovative, and cross-disciplinary cancer research to develop a cancer prevention therapy for RUNX1 familial platelet disorder (RUNX1-FPD) with predisposition to blood cancer. The program also aims to support, inform, educate, and connect patients, healthcare providers, researchers, and other stakeholders in the RUNX1 community.
About Alex’s Lemonade Stand Foundation
A non-profit changing the lives of children with cancer by funding impactful research, raising awareness, supporting families, and empowering everyone to help cure childhood cancer. RUNX1 Early Career Investigator Program – Basic and Translational Science The RUNX1 Research Program and Alex’s Lemonade Stand Foundation are delighted to continue their partnership and funding opportunity for early career investigators: the RRP and ALSF RUNX1 Early Career Investigator Program.
Key Objective
To promote the establishment of a new generation of basic and translational scientists interested in tackling inherited hematologic malignancy predisposition disorders with a focus on RUNX1-familial platelet disorder. We believe that providing capital to early career investigators not only injects funding to where it is needed most, but also cultivates a new cohort of investigators who will be invested in an area of research that historically has had limited attention. Program Description The RUNX1 Early Career Investigator grant is a three-year award designed to fund research investigating strategies that will lead to the development of therapies that will prevent the transition from pre-malignancy to overt hematologic malignancy in patients with RUNX1-FPD. The RUNX1 Research Program and ALSF host an annual scientific meeting that brings together grant recipients and other scientists. Grant recipients are expected to present their progress as part of the annual review.
Applicant Eligibility: must be met at the time of application
- Applicant institutions may be based in the U.S. or outside of the U.S. Applicants need not be United States citizens. Funds must be granted to non-profit institutions or organizations.
- Applicants must have an MD, PhD, or MD/PhD (DO, MBBS, or equivalent) and be within five years of their first faculty appointment as an Assistant Professor or equivalent tenure-track position. Associate and Full Professors are ineligible. If at the Instructor level, the applicant must submit a letter of support from their mentor at the sponsoring institution.
- A minimum of 75% of the applicant’s time during the award period must be allocated as protected time for all research activities. This percentage of time includes both activities on this grant and the applicant’s other research responsibilities.
- Applicants may have research grants from other funding sources during the award period, but there must be clear documentation of mechanisms to avoid scientific and budgetary overlap.
- Applicants must have research experience working in, and a deep understanding of, normal or malignant hematopoiesis and/or immunology.
- One resubmission of a previously unfunded application is allowed. Use the Resubmission section of the application to respond to the prior RRP/ALSF critique of the proposal. The response will be scored in the review process in addition to the criteria used for new applications. Resubmissions compete with new applicants for funding.